{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:31:17Z","timestamp":1790958677421,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Associazione Italiana Leucemia, Linfomi e Mieloma\u2014AIL ODV, Bologna"},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2016-02362532"],"award-info":[{"award-number":["RF-2016-02362532"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RF-2016-02362532"],"award-info":[{"award-number":["RF-2016-02362532"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG2014-15839"],"award-info":[{"award-number":["IG2014-15839"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In recent years, the immunoderivative (IMiD) agents have been extensively used for the treatment of multiple myeloma (MM). IMiDs and their newer derivatives CRBN E3 ligase modulator bind the E3 ligase substrate recognition adapter protein cereblon (CRBN), which has been recognized as one of the IMiDs\u2019 direct target proteins, and it is essential for the therapeutic effect of these agents.<\/jats:p><jats:p>High expression of CRBN was associated with improved clinical response in patients with MM treated with IMiDs, further confirming that the expression of IMiDs\u2019 direct target protein CRBN is required for the anti-MM activity. CRBN\u2019s central role as a target of IMiDs suggests potential utility as a predictive biomarker of response or resistance to IMiDs therapy. Additionally, the presence of alternatively spliced variants of CRBN in MM cells, especially those lacking the drug-binding domain for IMiDs, raise questions concerning their potential biological function, making difficult the transcript measurement, which leads to inaccurate overestimation of full-length CRBN transcripts. In sight of this, in the present study, we evaluated the CRBN expression, both full-length and spliced isoforms, by using real-time assay data from 87 patients and RNA sequencing data from 50 patients (<jats:italic>n<\/jats:italic>\u2009=\u2009137 newly diagnosed MM patients), aiming at defining CRBN\u2019s role as a predictive biomarker for response to IMiDs-based induction therapy. We found that the expression level of the spliced isoform tends to be higher in not-responding patients, confirming that the presence of a more CRBN spliced transcript predicts for lack of IMiDs response.<\/jats:p>","DOI":"10.1007\/s10238-023-01205-y","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T05:01:38Z","timestamp":1696914098000},"page":"5227-5239","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients"],"prefix":"10.1007","volume":"23","author":[{"given":"Enrica","family":"Borsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Mazzocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Flores","family":"Dico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Vigliotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Martello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Poletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Solli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Taurisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajsi","family":"Kanapari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazia","family":"Pistis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Tacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Pantani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Rocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Rizzello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Cavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Terragna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"issue":"3","key":"1205_CR1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/abbs\/gmt142","volume":"46","author":"X Chang","year":"2014","unstructured":"Chang X, Zhu Y, Shi C, Stewart AK. Mechanism of immunomodulatory drugs\u2019 action in the treatment of multiple myeloma. Acta Biochim Biophys Sin. 2014;46(3):240\u201353.","journal-title":"Acta Biochim Biophys Sin"},{"issue":"5971","key":"1205_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5971):1345\u201350.","journal-title":"Science"},{"issue":"18","key":"1205_CR3","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","volume":"118","author":"YX Zhu","year":"2011","unstructured":"Zhu YX, Braggio E, Shi CX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118(18):4771\u20139.","journal-title":"Blood"},{"issue":"9","key":"1205_CR4","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nsmb.2874","volume":"21","author":"PP Chamberlain","year":"2014","unstructured":"Chamberlain PP, Lopez-Girona A, Miller K, et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014;21(9):803\u20139.","journal-title":"Nat Struct Mol Biol"},{"issue":"7512","key":"1205_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","volume":"512","author":"ES Fischer","year":"2014","unstructured":"Fischer ES, Bohm K, Lydeard JR, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014;512(7512):49\u201353.","journal-title":"Nature"},{"issue":"3","key":"1205_CR6","first-page":"287","volume":"2","author":"XB Chang","year":"2011","unstructured":"Chang XB, Stewart AK. What is the functional role of the thalidomide binding protein cereblon? Int J Biochem Mol Biol. 2011;2(3):287\u201394.","journal-title":"Int J Biochem Mol Biol"},{"issue":"4","key":"1205_CR7","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","volume":"124","author":"YX Zhu","year":"2014","unstructured":"Zhu YX, Braggio E, Shi CX, et al. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014;124(4):536\u201345.","journal-title":"Blood"},{"issue":"6168","key":"1205_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343(6168):305\u20139.","journal-title":"Science"},{"issue":"6168","key":"1205_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301\u20135.","journal-title":"Science"},{"issue":"6","key":"1205_CR10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol. 2014;164(6):811\u201321.","journal-title":"Br J Haematol"},{"issue":"3","key":"1205_CR11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s12185-014-1644-5","volume":"100","author":"T Yoshida","year":"2014","unstructured":"Yoshida T, Georgopoulos K. Ikaros fingers on lymphocyte differentiation. Int J Hematol. 2014;100(3):220\u20139.","journal-title":"Int J Hematol"},{"issue":"3","key":"1205_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/ni.2828","volume":"15","author":"TA Schwickert","year":"2014","unstructured":"Schwickert TA, Tagoh H, Gultekin S, et al. Stage-specific control of early B cell development by the transcription factor Ikaros. Nat Immunol. 2014;15(3):283\u201393.","journal-title":"Nat Immunol"},{"key":"1205_CR13","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1038\/bcj.2015.66","volume":"5","author":"CC Bjorklund","year":"2015","unstructured":"Bjorklund CC, Lu L, Kang J, et al. Rate of CRL4(CRBN) substrate Ikaros and aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 2015;5:e354.","journal-title":"Blood Cancer J"},{"issue":"7559","key":"1205_CR14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kronke","year":"2015","unstructured":"Kronke J, Fink EC, Hollenbach PW, et al. Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS. Nature. 2015;523(7559):183\u20138.","journal-title":"Nature"},{"issue":"7597","key":"1205_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nature16979","volume":"532","author":"G Petzold","year":"2016","unstructured":"Petzold G, Fischer ES, Thoma NH. Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4(CRBN) ubiquitin ligase. Nature. 2016;532(7597):127\u201330.","journal-title":"Nature"},{"issue":"7611","key":"1205_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela ME, Lu G, Ito T, et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature. 2016;535(7611):252\u20137.","journal-title":"Nature"},{"issue":"8","key":"1205_CR17","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.3324\/haematol.2017.186601","volume":"103","author":"LE Franssen","year":"2018","unstructured":"Franssen LE, Nijhof IS, Couto S, et al. Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients. Haematologica. 2018;103(8):e368\u201371.","journal-title":"Haematologica"},{"issue":"2","key":"1205_CR18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1182\/blood.2020007081","volume":"137","author":"S Gooding","year":"2021","unstructured":"Gooding S, Ansari-Pour N, Towfic F, et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood. 2021;137(2):232\u20137.","journal-title":"Blood"},{"issue":"9","key":"1205_CR19","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","volume":"128","author":"KM Kortum","year":"2016","unstructured":"Kortum KM, Mai EK, Hanafiah NH, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016;128(9):1226\u201333.","journal-title":"Blood"},{"issue":"11","key":"1205_CR20","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26(11):2326\u201335.","journal-title":"Leukemia"},{"issue":"5","key":"1205_CR21","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/leu.2013.315","volume":"28","author":"A Thakurta","year":"2014","unstructured":"Thakurta A, Gandhi AK, Waldman MF, et al. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia. 2014;28(5):1129\u201331.","journal-title":"Leukemia"},{"issue":"6","key":"1205_CR22","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/leu.2016.384","volume":"31","author":"J Kronke","year":"2017","unstructured":"Kronke J, Kuchenbauer F, Kull M, et al. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the german myeloma study group (DSMM). Leukemia. 2017;31(6):1363\u20137.","journal-title":"Leukemia"},{"issue":"1","key":"1205_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13045-016-0354-2","volume":"9","author":"M Pourabdollah","year":"2016","unstructured":"Pourabdollah M, Bahmanyar M, Atenafu EG, Reece D, Hou J, Chang H. High IKZF1\/3 protein expression is a favorable prognostic factor for survival of relapsed\/refractory multiple myeloma patients treated with lenalidomide. J Hematol Oncol. 2016;9(1):123.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1205_CR24","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1182\/blood.2019000789","volume":"134","author":"AS Sperling","year":"2019","unstructured":"Sperling AS, Burgess M, Keshishian H, et al. Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood. 2019;134(2):160\u201370.","journal-title":"Blood"},{"issue":"11","key":"1205_CR25","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41589-020-0645-3","volume":"16","author":"J Yamamoto","year":"2020","unstructured":"Yamamoto J, Suwa T, Murase Y, et al. ARID2 is a pomalidomide-dependent CRL4(CRBN) substrate in multiple myeloma cells. Nat Chem Biol. 2020;16(11):1208\u201317.","journal-title":"Nat Chem Biol"},{"key":"1205_CR26","unstructured":"Relating clinical outcomes in multiple myeloma to personal assessment of genetic Profile-Full Text View-ClinicalTrials.gov. [Internet]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01454297?term=NCT01454297&draw=2&rank=1."},{"key":"1205_CR27","doi-asserted-by":"publisher","first-page":"e418","DOI":"10.1200\/EDBK_159009","volume":"35","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV. Updated diagnostic criteria and staging system for multiple myeloma. Am Soc Clin Oncol Educ Book. 2016;35:e418\u201323.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"1205_CR28","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.trsl.2014.12.001","volume":"165","author":"E Borsi","year":"2015","unstructured":"Borsi E, Terragna C, Brioli A, Tacchetti P, Martello M, Cavo M. Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma. Transl Res. 2015;165(6):641\u201350.","journal-title":"Transl Res"},{"issue":"9","key":"1205_CR29","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/leu.2016.77","volume":"30","author":"M Martello","year":"2016","unstructured":"Martello M, Remondini D, Borsi E, et al. Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis. Leukemia. 2016;30(9):1869\u201376.","journal-title":"Leukemia"},{"issue":"7","key":"1205_CR30","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.18632\/oncotarget.1736","volume":"5","author":"E Borsi","year":"2014","unstructured":"Borsi E, Perrone G, Terragna C, et al. Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma. Oncotarget. 2014;5(7):1779\u201392.","journal-title":"Oncotarget"},{"issue":"12","key":"1205_CR31","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"3","key":"1205_CR32","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2(3):100141.","journal-title":"Innovation (Camb)."},{"issue":"2","key":"1205_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/bjh.12622","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi AK, Mendy D, Waldman M, et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol. 2014;164(2):233\u201344.","journal-title":"Br J Haematol"},{"issue":"2","key":"1205_CR34","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/bjh.12478","volume":"163","author":"L Lode","year":"2013","unstructured":"Lode L, Amiot M, Maiga S, et al. Cereblon expression in multiple myeloma: not ready for prime time. Br J Haematol. 2013;163(2):282\u20134.","journal-title":"Br J Haematol"},{"issue":"5","key":"1205_CR35","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/bjh.12291","volume":"161","author":"JB Egan","year":"2013","unstructured":"Egan JB, Kortuem KM, Kurdoglu A, et al. Extramedullary myeloma whole genome sequencing reveals novel mutations in cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol. 2013;161(5):748\u201351.","journal-title":"Br J Haematol"},{"issue":"5","key":"1205_CR36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/bjh.12338","volume":"161","author":"D Heintel","year":"2013","unstructured":"Heintel D, Rocci A, Ludwig H, et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol. 2013;161(5):695\u2013700.","journal-title":"Br J Haematol"},{"key":"1205_CR37","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1182\/blood-2021-147812","volume":"138","author":"G Paul","year":"2021","unstructured":"Paul G, Richardson EO, Raje NS, et al. CC-92480, a potent, novel cereblon E3 ligase modulator (CELMoD) agent, in combination with dexamethasone (DEX) and bortezomib (BORT) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): preliminary results from the phase 1\/2 study CC-92480-MM-002. Blood. 2021;138:2731.","journal-title":"Blood"},{"issue":"11","key":"1205_CR38","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","volume":"9","author":"S Lonial","year":"2022","unstructured":"Lonial S, Popat R, Hulin C, et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial. Lancet Haematol. 2022;9(11):e822\u201332.","journal-title":"Lancet Haematol"},{"issue":"4","key":"1205_CR39","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","volume":"34","author":"CC Bjorklund","year":"2020","unstructured":"Bjorklund CC, Kang J, Amatangelo M, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020;34(4):1197\u2013201.","journal-title":"Leukemia"},{"issue":"6619","key":"1205_CR40","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1126\/science.add7574","volume":"378","author":"R Edmond","year":"2022","unstructured":"Edmond R, Watson PJN, Matyskiela ME, Chamberlain PP, et al. Molecular glue CELMoD compounds are allosteric regulators of cereblon conformation. Science. 2022;378(6619):549\u201353.","journal-title":"Science"},{"issue":"13","key":"1205_CR41","doi-asserted-by":"publisher","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","volume":"63","author":"JD Hansen","year":"2020","unstructured":"Hansen JD, Correa M, Nagy MA, et al. Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma. J Med Chem. 2020;63(13):6648\u201376.","journal-title":"J Med Chem"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01205-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01205-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01205-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T16:22:28Z","timestamp":1702743748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01205-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1205"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01205-y","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"assertion":[{"value":"9 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients included in the study provided written informed consents for biological studies and have been treated following local recommendations for clinical trials or routine clinical practice at the Ser\u00e0gnoli Institute, IRCCS Azienda Ospedaliero-Universitaria of Bologna, Italy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors have approved the manuscript for submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}